Breaking News Instant updates and real-time market news.

FCX

Freeport McMoRan

$10.60

0.01 (0.09%)

, PFE

Pfizer

$42.39

-0.72 (-1.67%)

07:35
12/19/18
12/19
07:35
12/19/18
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Tuesday in Freeport McMoRan (FCX), Pfizer (PFE), First Data (FDC), Regions Financial (RF), Aphria (APHA), Signet Jewelers (SIG), and Navistar (NAV).

FCX

Freeport McMoRan

$10.60

0.01 (0.09%)

PFE

Pfizer

$42.39

-0.72 (-1.67%)

FDC

First Data

$16.60

0.18 (1.10%)

RF

Regions Financial

$13.23

-0.15 (-1.12%)

APHA

Aphria

$5.86

0.42 (7.72%)

SIG

Signet Jewelers

$31.23

-0.25 (-0.79%)

NAV

Navistar

$27.59

3.75 (15.73%)

  • 05

    Jan

  • 18

    Jan

  • 29

    Jan

  • 03

    Mar

FCX Freeport McMoRan
$10.60

0.01 (0.09%)

11/06/18
RBCM
11/06/18
DOWNGRADE
RBCM
Underperform
Freeport McMoRan downgraded to Underperform from Sector Perform at RBC Capital
11/07/18
RBCM
11/07/18
DOWNGRADE
Target $15
RBCM
Underperform
Freeport McMoRan downgraded to Underperform at RBC Capital on valuation
As noted earlier, RBC Capital analyst Stephen Walker downgraded Freeport McMoRan to Underperform from Sector Perform and lowered his price target to $15 from $16. The analyst points to the company's premium valuation ahead of what he expects to be a decline in 2019 production. Walker also cites Freeport McMoRan's operating risks associated with the transition from open-pit to underground mining at the Grasberg mine and the "integration risk associated with Inalum becoming a new partner."
11/07/18
11/07/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Freeport McMoRan (FCX) downgraded to Underperform from Sector Perform at RBC Capital with analyst Stephen Walker saying he points to the company's premium valuation ahead of what he expects to be a decline in 2019 production. 2. Zillow (Z, ZG) downgraded to Sell from Hold at Zelman and to Negative from Neutral at Susquehanna. 3. Mindbody (MB) downgraded to Neutral from Buy at UBS and Roth Capital as well as to Neutral from Overweight at JPMorgan. 4. Frontier Communications (FTR) downgraded to Sell from Neutral at UBS with analyst Batya Levi saying Frontier's free cash flow remains under pressure. 5. Audentes downgraded to Market Perform from Outperform at William Blair with analyst Raju Prasad saying increased competition in Pompe disease is giving him pause. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/18/18
DBAB
12/18/18
NO CHANGE
DBAB
Rio Tinto acquisitions part of Deutsche's 'left-field ideas' for miners
With the potential for slower growth in China, weaker iron ore prices and rising production costs, the Mining industry may consider bold actions in 2019, Deutsche Bank told investors in a research note. The firm's "left-field ideas" include Rio Tinto (RIO) possibly considering acquisitions of Anglo American (NGLOY), First Quantum Minerals (FQVLF) or Freeport McMoRan (FCX). Deutsche also thinks BHP Billiton (BHP) could further look to trim its portfolio with a spinoff that includes its Nickel West unit, oil and gas operations in Australia, and thermal coal in Colombia and Australia.
PFE Pfizer
$42.39

-0.72 (-1.67%)

11/19/18
CANT
11/19/18
NO CHANGE
Target $53
CANT
Overweight
Pfizer's oncology assets are underappreciated, says Cantor Fitzgerald
Pfizer's oncology assets will make up 13% of its total 2018 sales and they will accelerate the company's sales growth for the foreseeable future, but these drugs are underappreciated, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. Pfizer has said that through 2022 it expects 15 potential blockbusters to be launched, and oncology drugs are represented in these opportunities, the analyst points out. She sees upside to consensus estimates and keeps an Overweight rating on Pfizer with a $53 price target.
11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.
12/11/18
JPMS
12/11/18
DOWNGRADE
Target $46
JPMS
Neutral
Pfizer downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Christopher Schott downgraded Pfizer to Neutral with an unchanged price target of $46. The shares closed yesterday up 48c to $44.40. The analyst cites valuation for his move to the sidelines after a "strong" 2018 which has to the stock up over 20% year-to-date. Further, he believes Pfizer's product pipeline needs to expand following the patent expiration of Lyrica in 2019.
12/11/18
12/11/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Pfizer (PFE) downgraded to Neutral from Overweight at JPMorgan with analyst Christopher Schott citing valuation. 2. Splunk (SPLK) resumed with a Neutral from Buy at Guggenheim with analyst Imtiaz Koujalgi saying while the company's fundamentals are strong, he's "looking for more clarity." 3. CalAmp (CAMP) downgraded to Outperform from Strong Buy at First Analysis and to Market Perform from Outperform at Northland. 4. Acorda Therapeutics (ACOR) downgraded to Sell from Neutral at Goldman Sachs with analyst Salveen Richter saying the commercial outlook for Inbrija appears limited. 5. Versum Materials (VSM) downgraded to Sell from Neutral at Goldman Sachs with analyst Toshiya Hari saying while he remains constructive on the Semiconductor Materials sub-sector broadly, he believes the market is underestimating the extent to which weaker semiconductor capital expenditures could negatively impact the Delivery Systems and Services segment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
FDC First Data
$16.60

0.18 (1.10%)

11/08/18
SUSQ
11/08/18
DOWNGRADE
Target $77
SUSQ
Neutral
Square downgraded to Neutral on valuation, CFO vacancy at Susquehanna
As reported previously, Susquehanna analyst James Friedman downgraded Square (SQ) to Neutral from Positive. The analyst cited valuation and the lack of a CFO at the company. While he sees Square taking about ten billion of cumulative revenue share from incumbent merchant acquirers, ISOs and ISVs, he would await a better re-entry point pending management visibility, Friedman tells investors. In the meantime, Friedman suggests investors look at First Data (FDC) instead, stating that Clover is generally performing as well as Square's payments products while the stock's discount to Square "seems compelling." Friedman maintained his $77 price target on Square shares.
11/14/18
LEHM
11/14/18
INITIATION
Target $24
LEHM
Overweight
First Data initiated with an Overweight at Barclays
Barclays analyst Ramsey El-Assal initiated First Data with an Overweight and $24 price target.
11/14/18
LEHM
11/14/18
INITIATION
LEHM
Overweight
Barclays initiates coverage of U.S. payment processors with PayPal as top pick
As noted earlier, Barclays analyst Ramsey El-Assal initiated a group of 20 U.S. companies in the Payments, Processing, and related IT Services sector with Overweight-rated PayPal (PYPL) as his Top Pick. The analyst cites the company's "100% exposure to high-growth digital channels" along with its "clean balance sheet substantial cash position" that bring it a "strategic opportunity. El-Assal is also particularly positive on Overweight-rated WorldPay (WP) based on its strong growth potential from its exposure to "tech-enabled channels" and merger synergies, FirstData (FDC) based on the accelerating growth of its merchant channels, and Square (SQ)," whose Subscription & Services segment is blurring the lines between Payments and software". The analyst contends that the extent of being "tech-enabled" is a key differentiator in the Payments industry, assigning an Overweight rating to Alliance Data Systems (ADS), ADP (ADP), Cardtronics (CATM), Fidelity National (FIS), First Data (FDC), Fiserv (FISV), Fleetcor Technologies (FLT), Global Payments (GPN), Green Dot (GDOT), Mastercard (MA), Total System Services (TSS), Visa (V), and WEX Inc (WEX). El-Assal assigns Equal-weight ratings to EVO Payments (EVOP) and Paychex (PAYX), stating that while the companies are "solid performers" in the space, their valuation is seen as more balanced. The analyst rates MoneyGram (MGI) and Western Union (WU) at Underweight, saying that the former will struggle to re-ignite positive growth as the costs associated with regulatory scrutiny weigh on its profits and the latter will be challenged by "periodic pricing pressure eroding margins over a long period of time."
11/23/18
WEDB
11/23/18
NO CHANGE
Target $30
WEDB
Outperform
First Data should be bought on recent weakness, says Wedbush
Wedbush analyst Moshe Katri keeps an Outperform rating on First Data Corp. with a $30 price target following the company's "mixed" Q3 results. The stock closed Wednesday at $17.46. Multiple factors, including currency headwinds, acquisition dilution, the new accounting standard and divestitures impacted reported sales and profitability, Katri tells investors in a research note. The analyst recommends buying the stock on the recent weakness saying the thesis is intact. First Data remains well positioned to capitalize on strength in merchant/financial processing combined with gradual deleveraging in its balance sheet, says the analyst.
RF Regions Financial
$13.23

-0.15 (-1.12%)

12/10/18
NOMU
12/10/18
DOWNGRADE
Target $14
NOMU
Reduce
Regions Financial downgraded to Reduce with $14 target at Nomura Instinet
Nomura Instinet analyst Bill Carcache downgraded Regions Financial to Reduce from Neutral and lowered his price target for the shares to $14 from $17. Accelerating commercial and industrial loan losses with drive negative earnings revisions and the shares to underperform regional peers, Carcache tells investors in a research note. He believes Regions growing C&I loans at rates above the industry will bring greater than expected loan losses.
12/10/18
NOMU
12/10/18
DOWNGRADE
Target $16
NOMU
Reduce
KeyCorp downgraded to Reduce with $16 target at Nomura Instinet
Nomura Instinet analyst Bill Carcache downgraded KeyCorp (KEY) to Reduce from Neutral and lowered his price target for the shares to $16 from $18. Accelerating commercial and industrial loan losses with drive negative earnings revisions and the shares to underperform regional peers, Carcache tells investors in a research note. He believes KeyCorp growing C&I loans at rates above the industry will bring greater than expected loan losses. The analyst this morning also downgraded Regions Financial (RF) to Reduced citing as similar rationale.
12/10/18
12/10/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. FedEx (FDX) downgraded to Neutral from Buy at BofA/Merrill with analyst Ken Hoexter citing the board's surprise move to change its Express CEO. 2. Unilever downgraded to Underweight from Neutral at JPMorgan with analyst Celine Pannuti saying she views consensus expectations as elevated. 3. Regions Financial (RF) and KeyCorp (KEY) were downgraded to Reduce from Neutral at Nomura Instinet. 4. Qorvo (QRVO) and Skyworks (SWKS) were downgraded to Sector Weight from Overweight at KeyBanc. 5. Navistar (NAV) and Oshkosh (OSK) were downgraded to Sell from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/10/18
NOMU
12/10/18
DOWNGRADE
NOMU
Reduce
Regions Financial downgraded to Reduce from Neutral at Nomura Instinet
APHA Aphria
$5.86

0.42 (7.72%)

SIG Signet Jewelers
$31.23

-0.25 (-0.79%)

10/26/18
SBSH
10/26/18
UPGRADE
Target $52
SBSH
Neutral
Signet Jewelers upgraded to Neutral from Sell at Citi
Citi analyst Paul Lejuez upgraded Signet Jewelers to Neutral with an unchanged price target of $52. The analyst cites valuation for the upgrade following "fast decline" in the shares.
12/10/18
NOMU
12/10/18
NO CHANGE
Target $42
NOMU
Neutral
Signet Jewelers price target lowered to $42 from $62 at Nomura Instinet
Nomura Instinet Simeon Siegel lowered his price target for Signet Jewelers to $42 saying management on the Q3 earnings call repeatedly stressed the need for promotions given slow moving product coupled with competitor pressure. The analyst remains concerned about Signet's "internal hurdles and external promotional challenges." He keeps a Neutral rating on the shares.
12/07/18
RBCM
12/07/18
NO CHANGE
Target $46
RBCM
Sector Perform
Signet Jewelers price target lowered to $46 from $69 at RBC Capital
RBC Capital analyst Brian Tunick lowered his price target on Signet Jewelers to $46 and kept his Sector Perform rating after its Q3 results. The analyst notes that while the earnings and revenues were in-line, he was disappointed by the company's cut in Q4 EBIT outlook amid increasingly more promotional environment that is weighing on its margins. Tunick adds that his new price target models a 12-times forward earnings multiple and reflects a "more cautious view on the earnings recovery given limited visibility into sales and margins."
12/03/18
NEED
12/03/18
NO CHANGE
NEED
Hold
Needham has 'low vsibility' on Signet Jewelers Q3 earnings this week
Needham analyst Rick Patel keeps his Hold rating on Signet Jewelers ahead of its Q3 results this Wednesday. The analyst notes that there is some potential of a "comp-driven EPS beat on conservative guidance", but also believes that investors will be more focused on the company's outlook. Patel further states that he anticipates Signet Jewelers to be "less promotional" in Q3, but adds that his early Holiday season checks look "mixed".
NAV Navistar
$27.59

3.75 (15.73%)

12/10/18
GSCO
12/10/18
DOWNGRADE
Target $23
GSCO
Sell
Navistar downgraded to Sell at Goldman Sachs on peaking truck production
As reported earlier, Goldman Sachs analyst Jerry Revich downgraded Navistar to Sell from Neutral and lowered his price target to $23 from $43 as part of his broader research note on the Engineering & Construction sector which requires a more selective positioning amid "growing signs of oversupply". The analyst expects a downturn in U.S. truck production to become evident by the end of next year and weigh on margins, even though the business trades "at the high end of its historical enterprise value to EBITDA valuation range. Revich adds that while the US truck demand accelerated in 2016-17 amid a "sharp increase in spot rates born of low capital stock, low unemployment, and electronic logging standards that reduced effective capacity", supply has now caught up with demand.
12/10/18
GSCO
12/10/18
DOWNGRADE
Target $23
GSCO
Sell
Navistar downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Jerry Revich downgraded Navistar International to Sell and lowered his price target for the shares to $23 from $43. The analyst recommends an increasingly selective approach for the Americas Machinery, Engineering & Construction sector in 2019 amid growing signs of oversupply.
12/06/18
LOOP
12/06/18
UPGRADE
Target $44
LOOP
Buy
Navistar upgraded to Buy from Hold at Loop Capital
Loop Capital analyst Jeffrey Kauffman upgraded Navistar to Buy from Hold and raised his price target to $44 from $42, saying his confidence in the company's prospects and strategic initiatives has increased even as the stock price has declined 22% since the start of Q4. The analyst contends that the pullback offers an "attractive entry opportunity", particularly given the management's efforts to "improve the company's financial and competitive position" and investors' lagging adjustment to reflect the market share gains. Kauffman adds that amid the pessimism of a peaking Class 8 truck cycle, an increasing component of Navistar's earnings is coming from medium duty trucks, with the negative cycle impact further dampened by the company's market share gains and improving operating performance.

TODAY'S FREE FLY STORIES

WAIR

Wesco Aircraft

$11.01

0.01 (0.09%)

16:46
10/18/19
10/18
16:46
10/18/19
16:46
Conference/Events
Wesco Aircraft to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:41
10/18/19
10/18
16:41
10/18/19
16:41
Hot Stocks
Breaking Hot Stocks news story on Foamix »

Foamix up 7.5% at $3.35…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

POAI

Predictive Oncology

$0.44

0.0101 (2.35%)

16:40
10/18/19
10/18
16:40
10/18/19
16:40
Conference/Events
Predictive Oncology to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BK

BNY Mellon

$45.34

0.975 (2.20%)

16:40
10/18/19
10/18
16:40
10/18/19
16:40
Hot Stocks
BNY Mellon SVP Harris sells 50K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:40
10/18/19
10/18
16:40
10/18/19
16:40
Hot Stocks
Breaking Hot Stocks news story on Foamix 

Foamix trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

BAC

Bank of America

$30.37

0.1 (0.33%)

16:35
10/18/19
10/18
16:35
10/18/19
16:35
Hot Stocks
Bank of America's Knox sells 40,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 15

    Jan

LGC

Legacy Acquisition Corp

$10.24

0.02 (0.20%)

16:34
10/18/19
10/18
16:34
10/18/19
16:34
Conference/Events
Legacy Acquisition Corp to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFGP

Micro Focus

$15.13

0.56 (3.84%)

, OTEX

OpenText

$39.30

-1.545 (-3.78%)

16:33
10/18/19
10/18
16:33
10/18/19
16:33
Periodicals
OpenText weighing takeover bid for rival Micro Focus, Bloomberg says »

Open Text (OTEX) is…

MFGP

Micro Focus

$15.13

0.56 (3.84%)

OTEX

OpenText

$39.30

-1.545 (-3.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 19

    Nov

16:30
10/18/19
10/18
16:30
10/18/19
16:30
Options
Preliminary option volume of 21.9M today »

Preliminary option volume…

BA

Boeing

$344.01

-25.12 (-6.81%)

, ORCL

Oracle

$54.55

-0.52 (-0.94%)

16:22
10/18/19
10/18
16:22
10/18/19
16:22
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. earnings have…

BA

Boeing

$344.01

-25.12 (-6.81%)

ORCL

Oracle

$54.55

-0.52 (-0.94%)

KO

Coca-Cola

$54.78

0.98 (1.82%)

AXP

American Express

$116.82

-2.35 (-1.97%)

JNJ

Johnson & Johnson

$127.73

-8.47 (-6.22%)

M

Macy's

$15.11

-0.66 (-4.19%)

LB

L Brands

$16.32

-1.78 (-9.83%)

GPS

Gap

$16.87

-0.71 (-4.04%)

LEVI

Levi Strauss

$17.12

0.07 (0.41%)

DERM

Dermira

$7.17

1.49 (26.23%)

ETFC

E-Trade

$40.82

1.78 (4.56%)

GIL

Gildan Activewear

$26.29

-9.085 (-25.68%)

TEAM

Atlassian

$116.96

-5.47 (-4.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 31

    Oct

  • 13

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 06

    Dec

  • 07

    Dec

EYEG

EyeGate

$3.40

(0.00%)

16:20
10/18/19
10/18
16:20
10/18/19
16:20
Syndicate
Breaking Syndicate news story on EyeGate »

EyeGate files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
10/18/19
10/18
16:20
10/18/19
16:20
Options
Closing CBOE SPX and VIX Index summary for October 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTOR

Meritor

$20.36

0.36 (1.80%)

16:17
10/18/19
10/18
16:17
10/18/19
16:17
Hot Stocks
Glenview Capital discloses 14.7% activist stake in Meritor »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BCBP

BCB Bancorp

$12.91

-0.04 (-0.31%)

16:17
10/18/19
10/18
16:17
10/18/19
16:17
Earnings
BCB Bancorp reports Q3 EPS 30c, consensus 30c »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
10/18/19
10/18
16:17
10/18/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
10/18/19
10/18
16:16
10/18/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTI

Universal Technical

$5.35

0.12 (2.29%)

16:15
10/18/19
10/18
16:15
10/18/19
16:15
Syndicate
Breaking Syndicate news story on Universal Technical »

Universal Technical files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$246.37

2.62 (1.07%)

16:13
10/18/19
10/18
16:13
10/18/19
16:13
Hot Stocks
UnitedHealth's Burke sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:09
10/18/19
10/18
16:09
10/18/19
16:09
Hot Stocks
Foamix announces FDA approval of AMZEEQ topical foam, 4% »

Foamix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

KWR

Quaker Chemical

$160.98

-2.04 (-1.25%)

16:05
10/18/19
10/18
16:05
10/18/19
16:05
Earnings
Quaker Houghton sees Q3 net sales $325M, consensus $348.82M »

Michael F. Barry,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KWR

Quaker Chemical

$160.98

-2.04 (-1.25%)

16:05
10/18/19
10/18
16:05
10/18/19
16:05
Earnings
Quaker Houghton sees FY19 pro forma adjusted EBITDA down 2%-4% »

Quaker Houghton updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$36.28

0.08 (0.22%)

16:04
10/18/19
10/18
16:04
10/18/19
16:04
Periodicals
GM to build new electric pickups, SUVs at Detrioit-Hamtramck plant, Reuters says »

Beginning in late 2021,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

FCCY

1st Constitution Bancorp

$19.04

-0.09 (-0.47%)

, SHRC

Shore Community Bank

$0.00

(0.00%)

16:02
10/18/19
10/18
16:02
10/18/19
16:02
Hot Stocks
Shore shareholders approve of merger with 1st Constitution Bancorp »

1ST Constitution Bancorp…

FCCY

1st Constitution Bancorp

$19.04

-0.09 (-0.47%)

SHRC

Shore Community Bank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CHMG

Chemung Financial

$42.84

-0.09 (-0.21%)

16:01
10/18/19
10/18
16:01
10/18/19
16:01
Earnings
Chemung Financial reports Q3 EPS 40c, consensus 29c »

Anders Tomson, Chemung…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

GM

General Motors

$36.30

0.1 (0.28%)

15:55
10/18/19
10/18
15:55
10/18/19
15:55
Periodicals
Breaking Periodicals news story on General Motors »

GM to build new electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.